Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Rheumatoid Arthritis

  Free Subscription


Articles published in Arthritis Res Ther

Retrieve available abstracts of 195 articles:
HTML format
Text format



Single Articles


    July 2019
  1. TOMIZAWA T, Ito H, Murata K, Hashimoto M, et al
    Distinct biomarkers for different bones in osteoporosis with rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:174.
    PubMed     Text format     Abstract available


  2. EUSTACE AD, McNaughton EF, King S, Kehoe O, et al
    Soluble syndecan-3 binds chemokines, reduces leukocyte migration in vitro and ameliorates disease severity in models of rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:172.
    PubMed     Text format     Abstract available


  3. PENG A, Lu X, Huang J, He M, et al
    Rheumatoid arthritis synovial fibroblasts promote TREM-1 expression in monocytes via COX-2/PGE2 pathway.
    Arthritis Res Ther. 2019;21:169.
    PubMed     Text format     Abstract available


  4. TANAKA Y, Smolen JS, Jones H, Szumski A, et al
    The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:164.
    PubMed     Text format     Abstract available


  5. TERSLEV L, Christensen R, Aga AB, Sexton J, et al
    Assessing synovitis in the hands in patients with rheumatoid arthritis by ultrasound: an agreement study exploring the most inflammatory active side from two Norwegian trials.
    Arthritis Res Ther. 2019;21:166.
    PubMed     Text format     Abstract available


    June 2019
  6. ELLEGAARD K, von Bulow C, Ropke A, Bartholdy C, et al
    Hand exercise for women with rheumatoid arthritis and decreased hand function: an exploratory randomized controlled trial.
    Arthritis Res Ther. 2019;21:158.
    PubMed     Text format     Abstract available


  7. MA JD, Jing J, Wang JW, Yan T, et al
    A novel function of artesunate on inhibiting migration and invasion of fibroblast-like synoviocytes from rheumatoid arthritis patients.
    Arthritis Res Ther. 2019;21:153.
    PubMed     Text format     Abstract available


  8. OZEN G, Pedro S, Schumacher R, Simon TA, et al
    Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study.
    Arthritis Res Ther. 2019;21:141.
    PubMed     Text format     Abstract available


  9. HU Y, Wang B, Shen J, Low SA, et al
    Depletion of activated macrophages with a folate receptor-beta-specific antibody improves symptoms in mouse models of rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:143.
    PubMed     Text format     Abstract available


  10. MOUTERDE G, Rincheval N, Lukas C, Daien C, et al
    Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort.
    Arthritis Res Ther. 2019;21:140.
    PubMed     Text format     Abstract available


  11. CHOQUETTE D, Bessette L, Alemao E, Haraoui B, et al
    Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata(R) clinical database and registry.
    Arthritis Res Ther. 2019;21:138.
    PubMed     Text format     Abstract available


  12. CAI Y, Jiang C, Zhu J, Xu K, et al
    miR-449a inhibits cell proliferation, migration, and inflammation by regulating high-mobility group box protein 1 and forms a mutual inhibition loop with Yin Yang 1 in rheumatoid arthritis fibroblast-like synoviocytes.
    Arthritis Res Ther. 2019;21:134.
    PubMed     Text format     Abstract available


    May 2019
  13. JAWORSKI J, Matucci-Cerinic M, Schulze-Koops H, Buch MH, et al
    Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-
    Arthritis Res Ther. 2019;21:130.
    PubMed     Text format     Abstract available


  14. MUSTONEN AM, Kakela R, Lehenkari P, Huhtakangas J, et al
    Distinct fatty acid signatures in infrapatellar fat pad and synovial fluid of patients with osteoarthritis versus rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:124.
    PubMed     Text format     Abstract available


  15. FAN Y, Yang X, Zhao J, Sun X, et al
    Cysteine-rich 61 (Cyr61): a biomarker reflecting disease activity in rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:123.
    PubMed     Text format     Abstract available


  16. PARK MC, Matsuno H, Kim J, Park SH, et al
    Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, d
    Arthritis Res Ther. 2019;21:122.
    PubMed     Text format     Abstract available


  17. ALIVERNINI S, Bruno D, Tolusso B, Bui L, et al
    Differential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor/anti-citrulline antibody-negative rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:116.
    PubMed     Text format     Abstract available


  18. LAMAS JR, Fernandez-Gutierrez B, Mucientes A, Marco F, et al
    RNA sequencing of mesenchymal stem cells reveals a blocking of differentiation and immunomodulatory activities under inflammatory conditions in rheumatoid arthritis patients.
    Arthritis Res Ther. 2019;21:112.
    PubMed     Text format     Abstract available


  19. EBINA K, Hashimoto M, Yamamoto W, Hirano T, et al
    Correction to: Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.
    Arthritis Res Ther. 2019;21:114.
    PubMed     Text format     Abstract available


    April 2019
  20. WINTHROP KL, Bingham CO 3rd, Komocsar WJ, Bradley J, et al
    Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy.
    Arthritis Res Ther. 2019;21:102.
    PubMed     Text format     Abstract available


  21. TAYLOR PC, Saurigny D, Vencovsky J, Takeuchi T, et al
    Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or
    Arthritis Res Ther. 2019;21:101.
    PubMed     Text format     Abstract available


  22. SUN X, Deng X, Xie W, Wang L, et al
    The agreement between ultrasound-determined joint inflammation and clinical signs in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:100.
    PubMed     Text format     Abstract available


  23. TANAKA Y, Wada K, Takahashi Y, Hagino O, et al
    Correction to: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan.
    Arthritis Res Ther. 2019;21:99.
    PubMed     Text format     Abstract available


  24. POLISKA S, Besenyei T, Vegh E, Hamar A, et al
    Gene expression analysis of vascular pathophysiology related to anti-TNF treatment in rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:94.
    PubMed     Text format     Abstract available


  25. EBINA K, Hashimoto M, Yamamoto W, Hirano T, et al
    Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.
    Arthritis Res Ther. 2019;21:91.
    PubMed     Text format     Abstract available


  26. WOLLENHAUPT J, Lee EB, Curtis JR, Silverfield J, et al
    Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.
    Arthritis Res Ther. 2019;21:89.
    PubMed     Text format     Abstract available


  27. SONG G, Lu Q, Fan H, Zhang X, et al
    Inhibition of hexokinases holds potential as treatment strategy for rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:87.
    PubMed     Text format     Abstract available


    March 2019
  28. COHEN S, Pablos JL, Pavelka K, Muller GA, et al
    An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:84.
    PubMed     Text format     Abstract available


  29. YU S, Lu Y, Zong M, Tan Q, et al
    Hypoxia-induced miR-191-C/EBPbeta signaling regulates cell proliferation and apoptosis of fibroblast-like synoviocytes from patients with rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:78.
    PubMed     Text format     Abstract available


  30. TANAKA Y, Wada K, Takahashi Y, Hagino O, et al
    Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan.
    Arthritis Res Ther. 2019;21:79.
    PubMed     Text format     Abstract available


  31. FERREIRA CC, Campi-Azevedo AC, Peruhype-Magalhaes V, Coelho-Dos-Reis JG, et al
    Impact of synthetic and biological immunomodulatory therapy on the duration of 17DD yellow fever vaccine-induced immunity in rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:75.
    PubMed     Text format     Abstract available


    February 2019
  32. MADISON A, Andersen BL, Ajam A
    Response to: "A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post hoc results from the certolizumab pegol phase 4 PREDICT trial".
    Arthritis Res Ther. 2019;21:65.
    PubMed     Text format    


  33. DAKKAK YJ, Boeters DM, Boer AC, Reijnierse M, et al
    What is the additional value of MRI of the foot to the hand in undifferentiated arthritis to predict rheumatoid arthritis development?
    Arthritis Res Ther. 2019;21:56.
    PubMed     Text format     Abstract available


  34. POOLMAN TM, Gibbs J, Walker AL, Dickson S, et al
    Rheumatoid arthritis reprograms circadian output pathways.
    Arthritis Res Ther. 2019;21:47.
    PubMed     Text format     Abstract available


  35. HAFSTROM I, Ajeganova S, Forslind K, Svensson B, et al
    Anti-citrullinated protein antibodies are associated with osteopenia but not with pain at diagnosis of rheumatoid arthritis: data from the BARFOT cohort.
    Arthritis Res Ther. 2019;21:45.
    PubMed     Text format     Abstract available


    January 2019
  36. VOMERO M, Manganelli V, Barbati C, Colasanti T, et al
    Reduction of autophagy and increase in apoptosis correlates with a favorable clinical outcome in patients with rheumatoid arthritis treated with anti-TNF drugs.
    Arthritis Res Ther. 2019;21:39.
    PubMed     Text format     Abstract available


  37. ATEHORTUA L, Rojas M, Vasquez G, Munoz-Vahos CH, et al
    Endothelial activation and injury by microparticles in patients with systemic lupus erythematosus and rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:34.
    PubMed     Text format     Abstract available


  38. GHOSH-SWABY OR, Kuriya B
    Awareness and perceived risk of cardiovascular disease among individuals living with rheumatoid arthritis is low: results of a systematic literature review.
    Arthritis Res Ther. 2019;21:33.
    PubMed     Text format     Abstract available


  39. DE MOEL EC, Derksen VFAM, Trouw LA, Bang H, et al
    In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response.
    Arthritis Res Ther. 2019;21:28.
    PubMed     Text format     Abstract available


  40. RODRIGUEZ-LOZANO B, Gonzalez-Febles J, Garnier-Rodriguez JL, Dadlani S, et al
    Association between severity of periodontitis and clinical activity in rheumatoid arthritis patients: a case-control study.
    Arthritis Res Ther. 2019;21:27.
    PubMed     Text format     Abstract available


  41. KONDO Y, Suzuki K, Inoue Y, Sakata K, et al
    Significant association between joint ultrasonographic parameters and synovial inflammatory factors in rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:14.
    PubMed     Text format     Abstract available


  42. TANNER MR, Pennington MW, Chauhan SS, Laragione T, et al
    KCa1.1 and Kv1.3 channels regulate the interactions between fibroblast-like synoviocytes and T lymphocytes during rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:6.
    PubMed     Text format     Abstract available


  43. KOPPEJAN H, Jansen DTSL, Hameetman M, Thomas R, et al
    Altered composition and phenotype of mucosal-associated invariant T cells in early untreated rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:3.
    PubMed     Text format     Abstract available


    December 2018
  44. ANDONIAN BJ, Bartlett DB, Huebner JL, Willis L, et al
    Effect of high-intensity interval training on muscle remodeling in rheumatoid arthritis compared to prediabetes.
    Arthritis Res Ther. 2018;20:283.
    PubMed     Text format     Abstract available


  45. INCIARTE-MUNDO J, Ramirez J, Hernandez MV, Ruiz-Esquide V, et al
    Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study.
    Arthritis Res Ther. 2018;20:275.
    PubMed     Text format     Abstract available


  46. BARBATI C, Vomero M, Colasanti T, Diociaiuti M, et al
    TNFalpha expressed on the surface of microparticles modulates endothelial cell fate in rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:273.
    PubMed     Text format     Abstract available


  47. CHEN YM, Chang CY, Chen HH, Hsieh CW, et al
    Association between autophagy and inflammation in patients with rheumatoid arthritis receiving biologic therapy.
    Arthritis Res Ther. 2018;20:268.
    PubMed     Text format     Abstract available


  48. PANOPOULOS S, Tektonidou M, Drosos AA, Liossis SN, et al
    Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study.
    Arthritis Res Ther. 2018;20:267.
    PubMed     Text format     Abstract available


  49. BISSELL LA, Erhayiem B, Fent G, Hensor EMA, et al
    Carotid artery volumetric measures associate with clinical ten-year cardiovascular (CV) risk scores and individual traditional CV risk factors in rheumatoid arthritis; a carotid-MRI feasibility study.
    Arthritis Res Ther. 2018;20:266.
    PubMed     Text format     Abstract available


    November 2018
  50. LOFGREN M, Opava CH, Demmelmaier I, Friden C, et al
    Long-term, health-enhancing physical activity is associated with reduction of pain but not pain sensitivity or improved exercise-induced hypoalgesia in persons with rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:262.
    PubMed     Text format     Abstract available


  51. TEN BRINCK RM, van Steenbergen HW, van der Helm-van Mil AHM
    Sequence of joint tissue inflammation during rheumatoid arthritis development.
    Arthritis Res Ther. 2018;20:260.
    PubMed     Text format     Abstract available


  52. ROODENRIJS NMT, de Hair MJH, Wheater G, Elshahaly M, et al
    The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies.
    Arthritis Res Ther. 2018;20:256.
    PubMed     Text format     Abstract available


    October 2018
  53. LEE YA, Hahm DH, Kim JY, Sur B, et al
    Potential therapeutic antibodies targeting specific adiponectin isoforms in rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:245.
    PubMed     Text format     Abstract available


  54. CONTRERAS-YANEZ I, Ruiz-Medrano E, Hernandez LDCR, Pascual-Ramos V, et al
    Psychometric validation of an empowerment scale for Spanish-speaking patients with rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:244.
    PubMed     Text format     Abstract available


  55. GUGGINO G, Orlando V, Saieva L, Ruscitti P, et al
    Downregulation of miRNA17-92 cluster marks Vgamma9Vdelta2 T cells from patients with rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:236.
    PubMed     Text format     Abstract available


  56. RITSCHL V, Lackner A, Bostrom C, Mosor E, et al
    I do not want to suppress the natural process of inflammation: new insights on factors associated with non-adherence in rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:234.
    PubMed     Text format     Abstract available


  57. TEITSMA XM, Yang W, Jacobs JWG, Petho-Schramm A, et al
    Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology.
    Arthritis Res Ther. 2018;20:230.
    PubMed     Text format     Abstract available


  58. DAVIGNON JL, Rauwel B, Degboe Y, Constantin A, et al
    Modulation of T-cell responses by anti-tumor necrosis factor treatments in rheumatoid arthritis: a review.
    Arthritis Res Ther. 2018;20:229.
    PubMed     Text format     Abstract available


  59. WANG S, Wang L, Wu C, Sun S, et al
    E2F2 directly regulates the STAT1 and PI3K/AKT/NF-kappaB pathways to exacerbate the inflammatory phenotype in rheumatoid arthritis synovial fibroblasts and mouse embryonic fibroblasts.
    Arthritis Res Ther. 2018;20:225.
    PubMed     Text format     Abstract available


  60. TERSLEV L, Ostergaard M, Sexton J, Hammer HB, et al
    Is synovial hypertrophy without Doppler activity sensitive to change? Post-hoc analysis from a rheumatoid arthritis ultrasound study.
    Arthritis Res Ther. 2018;20:224.
    PubMed     Text format     Abstract available


  61. ZHANG LM, Zhou JJ, Luo CL
    CYLD suppression enhances the pro-inflammatory effects and hyperproliferation of rheumatoid arthritis fibroblast-like synoviocytes by enhancing NF-kappaB activation.
    Arthritis Res Ther. 2018;20:219.
    PubMed     Text format     Abstract available


    September 2018
  62. SZEREMETA A, Jura-Poltorak A, Kozma EM, Glowacki A, et al
    Effects of a 15-month anti-TNF-alpha treatment on plasma levels of glycosaminoglycans in women with rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:211.
    PubMed     Text format     Abstract available


    August 2018
  63. THAI TN, Dawwas GK
    Comments on the article "Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study".
    Arthritis Res Ther. 2018;20:198.
    PubMed     Text format    


  64. NIU Q, Huang ZC, Wu XJ, Jin YX, et al
    Enhanced IL-6/phosphorylated STAT3 signaling is related to the imbalance of circulating T follicular helper/T follicular regulatory cells in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:200.
    PubMed     Text format     Abstract available


  65. IWAMOTO N, Fukui S, Takatani A, Shimizu T, et al
    Osteogenic differentiation of fibroblast-like synovial cells in rheumatoid arthritis is induced by microRNA-218 through a ROBO/Slit pathway.
    Arthritis Res Ther. 2018;20:189.
    PubMed     Text format     Abstract available


  66. FLEISCHMANN RM, Alten R, Pileckyte M, Lobello K, et al
    A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira(R)) in the treatment of active rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:178.
    PubMed     Text format     Abstract available


  67. JOHANSSON K, Askling J, Alfredsson L, Di Giuseppe D, et al
    Mediterranean diet and risk of rheumatoid arthritis: a population-based case-control study.
    Arthritis Res Ther. 2018;20:175.
    PubMed     Text format     Abstract available


  68. HASHIMOTO M, Furu M, Yamamoto W, Fujimura T, et al
    Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study.
    Arthritis Res Ther. 2018;20:165.
    PubMed     Text format     Abstract available


  69. NARASIMHAN R, Coras R, Rosenthal SB, Sweeney SR, et al
    Serum metabolomic profiling predicts synovial gene expression in rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:164.
    PubMed     Text format     Abstract available


  70. ISHII S, Isozaki T, Furuya H, Takeuchi H, et al
    ADAM-17 is expressed on rheumatoid arthritis fibroblast-like synoviocytes and regulates proinflammatory mediator expression and monocyte adhesion.
    Arthritis Res Ther. 2018;20:159.
    PubMed     Text format     Abstract available


    July 2018
  71. COHEN SB, Alten R, Kameda H, Hala T, et al
    A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.
    Arthritis Res Ther. 2018;20:155.
    PubMed     Text format     Abstract available


  72. ANGIOLILLI C, Kabala PA, Grabiec AM, Rossato M, et al
    Control of cytokine mRNA degradation by the histone deacetylase inhibitor ITF2357 in rheumatoid arthritis fibroblast-like synoviocytes: beyond transcriptional regulation.
    Arthritis Res Ther. 2018;20:148.
    PubMed     Text format     Abstract available


  73. ALDRIDGE J, Pandya JM, Meurs L, Andersson K, et al
    Sex-based differences in association between circulating T cell subsets and disease activity in untreated early rheumatoid arthritis patients.
    Arthritis Res Ther. 2018;20:150.
    PubMed     Text format     Abstract available


  74. TANAKA Y, Kameda H, Saito K, Kaneko Y, et al
    Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naive rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study.
    Arthritis Res Ther. 2018;20:151.
    PubMed     Text format     Abstract available


  75. JONSSON MK, Hensvold AH, Hansson M, Aga AB, et al
    The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy.
    Arthritis Res Ther. 2018;20:146.
    PubMed     Text format     Abstract available


  76. SERGEANT JC, Hyrich KL, Anderson J, Kopec-Harding K, et al
    Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS).
    Arthritis Res Ther. 2018;20:147.
    PubMed     Text format     Abstract available


    June 2018
  77. CHEN YL, Jing J, Mo YQ, Ma JD, et al
    Presence of hepatitis B virus in synovium and its clinical significance in rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:130.
    PubMed     Text format     Abstract available


  78. STRAND V, Gossec L, Proudfoot CWJ, Chen CI, et al
    Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:129.
    PubMed     Text format     Abstract available


  79. BARTLETT DB, Willis LH, Slentz CA, Hoselton A, et al
    Ten weeks of high-intensity interval walk training is associated with reduced disease activity and improved innate immune function in older adults with rheumatoid arthritis: a pilot study.
    Arthritis Res Ther. 2018;20:127.
    PubMed     Text format     Abstract available


  80. QIAN J, Xu L, Sun X, Wang Y, et al
    Correction to: Adiponectin aggravates bone erosion by promoting osteopontin production in synovial tissue of rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:125.
    PubMed     Text format     Abstract available


  81. CHANDRASEKHARAN UM, Wang Z, Wu Y, Wilson Tang WH, et al
    Elevated levels of plasma symmetric dimethylarginine and increased arginase activity as potential indicators of cardiovascular comorbidity in rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:123.
    PubMed     Text format     Abstract available


  82. RIVIERE E, Sellam J, Pascaud J, Ravaud P, et al
    Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:122.
    PubMed     Text format     Abstract available


    May 2018
  83. WEINBLATT ME
    Methotrexate: who would have predicted its importance in rheumatoid arthritis?
    Arthritis Res Ther. 2018;20:103.
    PubMed     Text format    


  84. RIFBJERG-MADSEN S, Christensen AW, Boesen M, Christensen R, et al
    The course of pain hypersensitivity according to painDETECT in patients with rheumatoid arthritis initiating treatment: results from the prospective FRAME-cohort study.
    Arthritis Res Ther. 2018;20:105.
    PubMed     Text format     Abstract available


  85. BALOGH E, Veale DJ, McGarry T, Orr C, et al
    Oxidative stress impairs energy metabolism in primary cells and synovial tissue of patients with rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:95.
    PubMed     Text format     Abstract available


  86. DRUCE KL, Aikman L, Dilleen M, Burden A, et al
    Fatigue independently predicts different work disability dimensions in etanercept-treated rheumatoid arthritis and ankylosing spondylitis patients.
    Arthritis Res Ther. 2018;20:96.
    PubMed     Text format     Abstract available


  87. BOETERS DM, Trouw LA, van der Helm-van Mil AHM, van Steenbergen HW, et al
    Does information on novel identified autoantibodies contribute to predicting the progression from undifferentiated arthritis to rheumatoid arthritis: a study on anti-CarP antibodies as an example.
    Arthritis Res Ther. 2018;20:94.
    PubMed     Text format     Abstract available


  88. BOER AC, Ten Brinck RM, Evers AWM, van der Helm-van Mil AHM, et al
    Does psychological stress in patients with clinically suspect arthralgia associate with subclinical inflammation and progression to inflammatory arthritis?
    Arthritis Res Ther. 2018;20:93.
    PubMed     Text format     Abstract available


  89. TEN BRINCK RM, Toes REM, van der Helm-van Mil AHM
    Inflammation functions as a key mediator in the link between ACPA and erosion development: an association study in Clinically Suspect Arthralgia.
    Arthritis Res Ther. 2018;20:89.
    PubMed     Text format     Abstract available


  90. RYDELL E, Forslind K, Nilsson JA, Jacobsson LTH, et al
    Smoking, body mass index, disease activity, and the risk of rapid radiographic progression in patients with early rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:82.
    PubMed     Text format     Abstract available


  91. ENGDAHL C, Bondt A, Harre U, Raufer J, et al
    Estrogen induces St6gal1 expression and increases IgG sialylation in mice and patients with rheumatoid arthritis: a potential explanation for the increased risk of rheumatoid arthritis in postmenopausal women.
    Arthritis Res Ther. 2018;20:84.
    PubMed     Text format     Abstract available


  92. COLE S, Walsh A, Yin X, Wechalekar MD, et al
    Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus.
    Arthritis Res Ther. 2018;20:85.
    PubMed     Text format     Abstract available


  93. KAN HJ, Dyagilev K, Schulam P, Saria S, et al
    Factors associated with physicians' prescriptions for rheumatoid arthritis drugs not filled by patients.
    Arthritis Res Ther. 2018;20:79.
    PubMed     Text format     Abstract available


  94. CHEN YL, Lin JZ, Mo YQ, Ma JD, et al
    Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study.
    Arthritis Res Ther. 2018;20:81.
    PubMed     Text format     Abstract available


    April 2018
  95. ZHOU YZ, Zhao LD, Chen H, Zhang Y, et al
    Comparison of the impact of Tripterygium wilfordii Hook F and Methotrexate treatment on radiological progression in active rheumatoid arthritis: 2-year follow up of a randomized, non-blinded, controlled study.
    Arthritis Res Ther. 2018;20:70.
    PubMed     Text format     Abstract available


  96. BURGERS LE, Boeters DM, Reijnierse M, van der Helm-van Mil AHM, et al
    Does the presence of magnetic resonance imaging-detected osteitis at diagnosis with rheumatoid arthritis lower the risk for achieving disease-modifying antirheumatic drug-free sustained remission: results of a longitudinal study.
    Arthritis Res Ther. 2018;20:68.
    PubMed     Text format     Abstract available


  97. KAWAGUCHI H, Matsumoto I, Osada A, Kurata I, et al
    Identification of novel biomarker as citrullinated inter-alpha-trypsin inhibitor heavy chain 4, specifically increased in sera with experimental and rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:66.
    PubMed     Text format     Abstract available


    March 2018
  98. MACHADO MAA, Moura CS, Guerra SF, Curtis JR, et al
    Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.
    Arthritis Res Ther. 2018;20:60.
    PubMed     Text format     Abstract available


  99. CAPPELLI LC, Konig MF, Gelber AC, Bingham CO 3rd, et al
    Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:59.
    PubMed     Text format     Abstract available


  100. GENOVESE M, Westhovens R, Meuleners L, Van der Aa A, et al
    Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes.
    Arthritis Res Ther. 2018;20:57.
    PubMed     Text format     Abstract available


  101. SUZUKI K, Yoshida K, Ueha T, Kaneshiro K, et al
    Methotrexate upregulates circadian transcriptional factors PAR bZIP to induce apoptosis on rheumatoid arthritis synovial fibroblasts.
    Arthritis Res Ther. 2018;20:55.
    PubMed     Text format     Abstract available


  102. MUELLER SM, Aguayo D, Aeberli D, Vogelin E, et al
    Myocellular characteristics in rheumatoid arthritis and osteoarthritis patients.
    Arthritis Res Ther. 2018;20:51.
    PubMed     Text format    


  103. BERGSTROM B, Carlsten H, Ekwall AH
    Methotrexate inhibits effects of platelet-derived growth factor and interleukin-1beta on rheumatoid arthritis fibroblast-like synoviocytes.
    Arthritis Res Ther. 2018;20:49.
    PubMed     Text format     Abstract available


  104. LOFGREN M, Opava CH, Demmelmaier I, Friden C, et al
    Pain sensitivity at rest and during muscle contraction in persons with rheumatoid arthritis: a substudy within the Physical Activity in Rheumatoid Arthritis 2010 study.
    Arthritis Res Ther. 2018;20:48.
    PubMed     Text format     Abstract available


  105. SCHWEDLER C, Haupl T, Kalus U, Blanchard V, et al
    Hypogalactosylation of immunoglobulin G in rheumatoid arthritis: relationship to HLA-DRB1 shared epitope, anticitrullinated protein antibodies, rheumatoid factor, and correlation with inflammatory activity.
    Arthritis Res Ther. 2018;20:44.
    PubMed     Text format     Abstract available


  106. WANG K, Zhang D, Liu Y, Wang X, et al
    Traditional Chinese medicine formula Bi-Qi capsule alleviates rheumatoid arthritis-induced inflammation, synovial hyperplasia, and cartilage destruction in rats.
    Arthritis Res Ther. 2018;20:43.
    PubMed     Text format     Abstract available


  107. TAKEUCHI T, Yamanaka H, Harigai M, Tamamura R, et al
    Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients.
    Arthritis Res Ther. 2018;20:42.
    PubMed     Text format     Abstract available


    February 2018
  108. HAHNLEIN JS, Nadafi R, de Jong T, Ramwadhdoebe TH, et al
    Impaired lymph node stromal cell function during the earliest phases of rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:35.
    PubMed     Text format     Abstract available


  109. DE MOEL EC, Derksen VFAM, Stoeken G, Trouw LA, et al
    Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes.
    Arthritis Res Ther. 2018;20:33.
    PubMed     Text format     Abstract available


  110. QIAN J, Xu L, Sun X, Wang Y, et al
    Adiponectin aggravates bone erosion by promoting osteopontin production in synovial tissue of rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:26.
    PubMed     Text format     Abstract available


    January 2018
  111. CHOWDHURY K, Kumar U, Das S, Chaudhuri J, et al
    Synovial IL-9 facilitates neutrophil survival, function and differentiation of Th17 cells in rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:18.
    PubMed     Text format     Abstract available


  112. TEN CATE DF, Jacobs JWG, Swen WAA, Hazes JMW, et al
    Can baseline ultrasound results help to predict failure to achieve DAS28 remission after 1 year of tight control treatment in early RA patients?
    Arthritis Res Ther. 2018;20:15.
    PubMed     Text format     Abstract available


  113. CHENG TT, Yu SF, Su FM, Chen YC, et al
    Anti-CCP-positive patients with RA have a higher 10-year probability of fracture evaluated by FRAX(R): a registry study of RA with osteoporosis/fracture.
    Arthritis Res Ther. 2018;20:16.
    PubMed     Text format     Abstract available


  114. SMOLEN JS, Szumski A, Koenig AS, Jones TV, et al
    Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
    Arthritis Res Ther. 2018;20:8.
    PubMed     Text format     Abstract available


  115. HARROLD LR, Litman HJ, Saunders KC, Dandreo KJ, et al
    One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.
    Arthritis Res Ther. 2018;20:2.
    PubMed     Text format     Abstract available


  116. ALTEN R, Burkhardt H, Feist E, Kruger K, et al
    Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting.
    Arthritis Res Ther. 2018;20:1.
    PubMed     Text format     Abstract available


    December 2017
  117. OUBOUSSAD L, Hunt L, Hensor EMA, Nam JL, et al
    Profiling microRNAs in individuals at risk of progression to rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:288.
    PubMed     Text format     Abstract available


  118. CHO SK, Lee J, Han M, Bae SC, et al
    The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs.
    Arthritis Res Ther. 2017;19:277.
    PubMed     Text format     Abstract available


  119. CURTIS JR, Winthrop K, O'Brien C, Ndlovu MN, et al
    Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment.
    Arthritis Res Ther. 2017;19:276.
    PubMed     Text format     Abstract available


  120. KUCA-WARNAWIN E, Kurowska W, Prochorec-Sobieszek M, Radzikowska A, et al
    Rheumatoid arthritis bone marrow environment supports Th17 response.
    Arthritis Res Ther. 2017;19:274.
    PubMed     Text format     Abstract available


  121. SATO H, Muraoka S, Kusunoki N, Masuoka S, et al
    Resistin upregulates chemokine production by fibroblast-like synoviocytes from patients with rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:263.
    PubMed     Text format     Abstract available


  122. LAI NS, Yu HC, Tung CH, Huang KY, et al
    The role of aberrant expression of T cell miRNAs affected by TNF-alpha in the immunopathogenesis of rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:261.
    PubMed     Text format     Abstract available


    November 2017
  123. BERGSTRA SA, Allaart CF, van den Berg R, Chopra A, et al
    Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:258.
    PubMed     Text format     Abstract available


  124. YANG X, Lin K, Ni S, Wang J, et al
    Serum connective tissue growth factor is a highly discriminatory biomarker for the diagnosis of rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:257.
    PubMed     Text format     Abstract available


  125. JIN S, Li M, Fang Y, Li Q, et al
    Chinese Registry of rheumatoid arthritis (CREDIT): II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:251.
    PubMed     Text format     Abstract available


  126. BLACK RJ, Lester S, Buchbinder R, Barrett C, et al
    Factors associated with oral glucocorticoid use in patients with rheumatoid arthritis: a drug use study from a prospective national biologics registry.
    Arthritis Res Ther. 2017;19:253.
    PubMed     Text format     Abstract available


  127. ZHOU L, Wang G, Liu X, Song J, et al
    Matrix metalloproteinase-3 and the 7-joint ultrasound score in the assessment of disease activity and therapeutic efficacy in patients with moderate to severe rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:250.
    PubMed     Text format     Abstract available


  128. ANAPARTI V, Smolik I, Meng X, Spicer V, et al
    Whole blood microRNA expression pattern differentiates patients with rheumatoid arthritis, their seropositive first-degree relatives, and healthy unrelated control subjects.
    Arthritis Res Ther. 2017;19:249.
    PubMed     Text format     Abstract available


    October 2017
  129. JOO YB, Kim Y, Park Y, Kim K, et al
    Biological function integrated prediction of severe radiographic progression in rheumatoid arthritis: a nested case control study.
    Arthritis Res Ther. 2017;19:244.
    PubMed     Text format     Abstract available


  130. ROMAO VC, Vital EM, Fonseca JE, Buch MH, et al
    Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?
    Arthritis Res Ther. 2017;19:239.
    PubMed     Text format     Abstract available


  131. MCQUEEN FM, Chapman P, Pollock T, D'Souza D, et al
    Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:241.
    PubMed     Text format     Abstract available


  132. MANDL T, Marsal J, Olsson P, Ohlsson B, et al
    Severe intestinal dysbiosis is prevalent in primary Sjogren's syndrome and is associated with systemic disease activity.
    Arthritis Res Ther. 2017;19:237.
    PubMed     Text format     Abstract available


  133. SAITO S, Suzuki K, Yoshimoto K, Kaneko Y, et al
    A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:231.
    PubMed     Text format     Abstract available


  134. TEJERA-SEGURA B, Lopez-Mejias R, Dominguez-Luis MJ, de Vera-Gonzalez AM, et al
    Incretins in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:229.
    PubMed     Text format     Abstract available


  135. SHIMIZU T, Choi HJ, Heilmeier U, Tanaka M, et al
    Assessment of 3-month changes in bone microstructure under anti-TNFalpha therapy in patients with rheumatoid arthritis using high-resolution peripheral quantitative computed tomography (HR-pQCT).
    Arthritis Res Ther. 2017;19:222.
    PubMed     Text format     Abstract available


  136. HAMMER HB, Kvien TK, Terslev L
    Ultrasound of the hand is sufficient to detect subclinical inflammation in rheumatoid arthritis remission: a post hoc longitudinal study.
    Arthritis Res Ther. 2017;19:221.
    PubMed     Text format     Abstract available


    September 2017
  137. BERGSTRA SA, Olivas O, Akdemir G, Riyazi N, et al
    Further Treatment Intensification in Undifferentiated and Rheumatoid Arthritis Patients Already in Low Disease Activity has Limited Benefit towards Physical Functioning.
    Arthritis Res Ther. 2017;19:220.
    PubMed     Text format     Abstract available


  138. SHERINA N, Hreggvidsdottir HS, Bengtsson C, Hansson M, et al
    Low levels of antibodies against common viruses associate with anti-citrullinated protein antibody-positive rheumatoid arthritis; implications for disease aetiology.
    Arthritis Res Ther. 2017;19:219.
    PubMed     Text format     Abstract available


  139. CURTIS JR, Herrem C, Ndlovu 'N, O'Brien C, et al
    A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial.
    Arthritis Res Ther. 2017;19:215.
    PubMed     Text format     Abstract available


  140. OLAH C, Kardos Z, Sepsi M, Sas A, et al
    Assessment of intracranial vessels in association with carotid atherosclerosis and brain vascular lesions in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:213.
    PubMed     Text format     Abstract available


  141. CHALLA DN, Kvrgic Z, Cheville AL, Crowson CS, et al
    Patient-provider discordance between global assessments of disease activity in rheumatoid arthritis: a comprehensive clinical evaluation.
    Arthritis Res Ther. 2017;19:212.
    PubMed     Text format     Abstract available


  142. SCHIFF M, Takeuchi T, Fleischmann R, Gaich CL, et al
    Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.
    Arthritis Res Ther. 2017;19:208.
    PubMed     Text format     Abstract available


  143. KABALA PA, Angiolilli C, Yeremenko N, Grabiec AM, et al
    Endoplasmic reticulum stress cooperates with Toll-like receptor ligation in driving activation of rheumatoid arthritis fibroblast-like synoviocytes.
    Arthritis Res Ther. 2017;19:207.
    PubMed     Text format     Abstract available


  144. TAKEUCHI T, Miyasaka N, Inui T, Yano T, et al
    High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the R
    Arthritis Res Ther. 2017;19:194.
    PubMed     Text format     Abstract available


  145. ZIEGELASCH M, Forslind K, Skogh T, Riklund K, et al
    Decrease in bone mineral density during three months after diagnosis of early rheumatoid arthritis measured by digital X-ray radiogrammetry predicts radiographic joint damage after one year.
    Arthritis Res Ther. 2017;19:195.
    PubMed     Text format     Abstract available


    August 2017
  146. SHAH NR, Noll BD, Stevens CB, Brennan MT, et al
    Biosemantics guided gene expression profiling of Sjogren's syndrome: a comparative analysis with systemic lupus erythematosus and rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:192.
    PubMed     Text format     Abstract available


  147. VAN DELFT MAM, Verheul MK, Burgers LE, Derksen VFAM, et al
    The isotype and IgG subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients.
    Arthritis Res Ther. 2017;19:190.
    PubMed     Text format     Abstract available


  148. NAKAGAWA J, Koyama Y, Kawakami A, Ueki Y, et al
    A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study.
    Arthritis Res Ther. 2017;19:185.
    PubMed     Text format     Abstract available


  149. LUNDSTROM SL, Hensvold AH, Rutishauser D, Klareskog L, et al
    IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:182.
    PubMed     Text format     Abstract available


    July 2017
  150. JAMSHIDI A, Gharibdoost F, Vojdanian M, Soroosh SG, et al
    A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA(R)) to the reference product (Humira(R)) in patients with active rheumat
    Arthritis Res Ther. 2017;19:168.
    PubMed     Text format     Abstract available


  151. TEITSMA XM, Jacobs JWG, Mokry M, Borm MEA, et al
    Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy.
    Arthritis Res Ther. 2017;19:170.
    PubMed     Text format     Abstract available


  152. MACLAUCHLAN S, Zuriaga MA, Fuster JJ, Cuda CM, et al
    Genetic deficiency of Wnt5a diminishes disease severity in a murine model of rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:166.
    PubMed     Text format     Abstract available


  153. BONDT A, Nicolardi S, Jansen BC, Kuijper TM, et al
    IgA N- and O-glycosylation profiling reveals no association with the pregnancy-related improvement in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:160.
    PubMed     Text format     Abstract available


  154. JIN Y, Desai RJ, Liu J, Choi NK, et al
    Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:159.
    PubMed     Text format     Abstract available


  155. SCHOELS M, Alasti F, Smolen JS, Aletaha D, et al
    Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition.
    Arthritis Res Ther. 2017;19:155.
    PubMed     Text format     Abstract available


  156. CASTANEDA S, Llorente I, Garcia-Vicuna R, Gonzalez-Alvaro I, et al
    Anti-citrullinated protein antibodies and bone loss in patients with early arthritis: comment on the article "Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untr
    Arthritis Res Ther. 2017;19:152.
    PubMed     Text format    


  157. OH BR, Suh DH, Bae D, Ha N, et al
    Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro.
    Arthritis Res Ther. 2017;19:154.
    PubMed     Text format     Abstract available


    June 2017
  158. KOKKONEN H, Stenlund H, Rantapaa-Dahlqvist S
    Cardiovascular risk factors predate the onset of symptoms of rheumatoid arthritis: a nested case-control study.
    Arthritis Res Ther. 2017;19:148.
    PubMed     Text format     Abstract available


  159. CABRERA-VILLALBA S, Gomara MJ, Canete JD, Ramirez J, et al
    Differing specificities and isotypes of anti-citrullinated peptide/protein antibodies in palindromic rheumatism and rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:141.
    PubMed     Text format     Abstract available


  160. SOLOMON DH, Shadick NA, Weinblatt ME, Zak A, et al
    Drug safety analyses in a rheumatoid arthritis registry: application of different approaches regarding timing of exposure and confounder measurement.
    Arthritis Res Ther. 2017;19:130.
    PubMed     Text format     Abstract available


  161. WANG J, Wen Y, Zhou M, Shi X, et al
    Ectopic germinal center and megalin defect in primary Sjogren syndrome with renal Fanconi syndrome.
    Arthritis Res Ther. 2017;19:120.
    PubMed     Text format     Abstract available


    May 2017
  162. TEJERA-SEGURA B, Macia-Diaz M, Machado JD, de Vera-Gonzalez A, et al
    HDL cholesterol efflux capacity in rheumatoid arthritis patients: contributing factors and relationship with subclinical atherosclerosis.
    Arthritis Res Ther. 2017;19:113.
    PubMed     Text format     Abstract available


  163. BOETERS DM, Mangnus L, Ajeganova S, Lindqvist E, et al
    The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical.
    Arthritis Res Ther. 2017;19:115.
    PubMed     Text format     Abstract available


  164. YOO J, Lee SK, Lim M, Sheen D, et al
    Exosomal amyloid A and lymphatic vessel endothelial hyaluronic acid receptor-1 proteins are associated with disease activity in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:119.
    PubMed     Text format     Abstract available


  165. BUSTAMANTE MF, Garcia-Carbonell R, Whisenant KD, Guma M, et al
    Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:110.
    PubMed     Text format     Abstract available


  166. SHODA H, Nagafuchi Y, Tsuchida Y, Sakurai K, et al
    Increased serum concentrations of IL-1 beta, IL-21 and Th17 cells in overweight patients with rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:111.
    PubMed     Text format     Abstract available


  167. CHANDRUPATLA DMSH, Jansen G, Vos R, Verlaan M, et al
    In-vivo monitoring of anti-folate therapy in arthritic rats using [(18)F]fluoro-PEG-folate and positron emission tomography.
    Arthritis Res Ther. 2017;19:114.
    PubMed     Text format     Abstract available


  168. ALDRICH MB, Velasquez FC, Kwon S, Azhdarinia A, et al
    Lymphatic delivery of etanercept via nanotopography improves response to collagen-induced arthritis.
    Arthritis Res Ther. 2017;19:116.
    PubMed     Text format     Abstract available


  169. KAWASHIRI SY, Fujikawa K, Nishino A, Okada A, et al
    Ultrasound-detected bone erosion is a relapse risk factor after discontinuation of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis whose ultrasound power Doppler synovitis activity and clinical disease activity are
    Arthritis Res Ther. 2017;19:108.
    PubMed     Text format     Abstract available


  170. GOIN DE, Smed MK, Pachter L, Purdom E, et al
    Pregnancy-induced gene expression changes in vivo among women with rheumatoid arthritis: a pilot study.
    Arthritis Res Ther. 2017;19:104.
    PubMed     Text format     Abstract available


  171. DERAMBURE C, Dzangue-Tchoupou G, Berard C, Vergne N, et al
    Pre-silencing of genes involved in the electron transport chain (ETC) pathway is associated with responsiveness to abatacept in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:109.
    PubMed     Text format     Abstract available


  172. PENATTI A, Facciotti F, De Matteis R, Larghi P, et al
    Differences in serum and synovial CD4+ T cells and cytokine profiles to stratify patients with inflammatory osteoarthritis and rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:103.
    PubMed     Text format     Abstract available


  173. THIEL J, Rizzi M, Engesser M, Dufner AK, et al
    B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.
    Arthritis Res Ther. 2017;19:101.
    PubMed     Text format     Abstract available


  174. NAKACHI S, Sumitomo S, Tsuchida Y, Tsuchiya H, et al
    Interleukin-10-producing LAG3+ regulatory T cells are associated with disease activity and abatacept treatment in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:97.
    PubMed     Text format     Abstract available


  175. GRABNER M, Boytsov NN, Huang Q, Zhang X, et al
    Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis.
    Arthritis Res Ther. 2017;19:92.
    PubMed     Text format     Abstract available


  176. STANDISH KA, Huang CC, Curran ME, Schork NJ, et al
    Comprehensive analysis of treatment response phenotypes in rheumatoid arthritis for pharmacogenetic studies.
    Arthritis Res Ther. 2017;19:90.
    PubMed     Text format     Abstract available


  177. SAUER BC, Teng CC, Accortt NA, Burningham Z, et al
    Models solely using claims-based administrative data are poor predictors of rheumatoid arthritis disease activity.
    Arthritis Res Ther. 2017;19:86.
    PubMed     Text format     Abstract available


  178. RYKOVA E, Sizikov A, Roggenbuck D, Antonenko O, et al
    Circulating DNA in rheumatoid arthritis: pathological changes and association with clinically used serological markers.
    Arthritis Res Ther. 2017;19:85.
    PubMed     Text format     Abstract available


    April 2017
  179. REED GW, Collier DH, Koenig AS, Saunders KC, et al
    Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:81.
    PubMed     Text format     Abstract available


  180. ISSA SF, Duer A, Ostergaard M, Horslev-Petersen K, et al
    Increased galectin-3 may serve as a serologic signature of pre-rheumatoid arthritis while markers of synovitis and cartilage do not differ between early undifferentiated arthritis subsets.
    Arthritis Res Ther. 2017;19:80.
    PubMed     Text format     Abstract available


  181. KUIJPER TM, Folmer R, Stolk EA, Hazes JMW, et al
    Doctors' preferences in de-escalating DMARDs in rheumatoid arthritis: a discrete choice experiment.
    Arthritis Res Ther. 2017;19:78.
    PubMed     Text format     Abstract available


  182. ANDRES CEREZO L, Sumova B, Prajzlerova K, Veigl D, et al
    Calgizzarin (S100A11): a novel inflammatory mediator associated with disease activity of rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:79.
    PubMed     Text format     Abstract available


  183. KUULIALA K, Kuuliala A, Koivuniemi R, Kautiainen H, et al
    Baseline JAK phosphorylation profile of peripheral blood leukocytes, studied by whole blood phosphospecific flow cytometry, is associated with 1-year treatment response in early rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:75.
    PubMed     Text format     Abstract available


  184. TAKAHASHI S, Saegusa J, Sendo S, Okano T, et al
    Glutaminase 1 plays a key role in the cell growth of fibroblast-like synoviocytes in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:76.
    PubMed     Text format     Abstract available


  185. KILTZ U, von Zabern C, Baraliakos X, Heldmann F, et al
    Diagnostic value of a 3-day course of prednisolone in patients with possible rheumatoid arthritis - the TryCort study.
    Arthritis Res Ther. 2017;19:73.
    PubMed     Text format     Abstract available


    March 2017
  186. MENG W, Zhu Z, Jiang X, Too CL, et al
    DNA methylation mediates genotype and smoking interaction in the development of anti-citrullinated peptide antibody-positive rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:71.
    PubMed     Text format     Abstract available


  187. ALBRECHT K, Zink A
    Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies.
    Arthritis Res Ther. 2017;19:68.
    PubMed     Text format     Abstract available


  188. JIANG J, Liu C, Liu M, Shen Y, et al
    OX40 signaling is involved in the autoactivation of CD4+CD28- T cells and contributes to the pathogenesis of autoimmune arthritis.
    Arthritis Res Ther. 2017;19:67.
    PubMed     Text format     Abstract available


  189. VAN DEN BRANDT S, Zbinden A, Baeten D, Villiger PM, et al
    Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients.
    Arthritis Res Ther. 2017;19:64.
    PubMed     Text format     Abstract available


  190. PERES RS, Santos GB, Cecilio NT, Jabor VA, et al
    Lapachol, a compound targeting pyrimidine metabolism, ameliorates experimental autoimmune arthritis.
    Arthritis Res Ther. 2017;19:47.
    PubMed     Text format     Abstract available


  191. CURTIS JR, Chen L, Higginbotham P, Nowell WB, et al
    Social media for arthritis-related comparative effectiveness and safety research and the impact of direct-to-consumer advertising.
    Arthritis Res Ther. 2017;19:48.
    PubMed     Text format     Abstract available


  192. OLSSON P, Turesson C, Mandl T, Jacobsson L, et al
    Cigarette smoking and the risk of primary Sjogren's syndrome: a nested case control study.
    Arthritis Res Ther. 2017;19:50.
    PubMed     Text format     Abstract available


    February 2017
  193. KLEYER A, Beyer L, Simon C, Stemmler F, et al
    Development of three-dimensional prints of arthritic joints for supporting patients' awareness to structural damage.
    Arthritis Res Ther. 2017;19:34.
    PubMed     Text format     Abstract available


  194. CROWLEY T, O'Neil JD, Adams H, Thomas AM, et al
    Priming in response to pro-inflammatory cytokines is a feature of adult synovial but not dermal fibroblasts.
    Arthritis Res Ther. 2017;19:35.
    PubMed     Text format     Abstract available


    January 2017
  195. AQRAWI LA, Galtung HK, Vestad B, Ovstebo R, et al
    Identification of potential saliva and tear biomarkers in primary Sjogren's syndrome, utilising the extraction of extracellular vesicles and proteomics analysis.
    Arthritis Res Ther. 2017;19:14.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Rheumatoid Arthritis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: